Breaking News

Teva To Acquire NuPathe

Expands CNS portfolio

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Teva Pharmaceutical Industries Ltd. has entered into a definitive agreement to acquire NuPathe Inc. for approximately $144 million in cash. NuPathe shareholders may also receive additional payments if sales milestones are met for NuPathe’s migraine treatment, ZECUITY. The transaction is expected to close in February 2014.   Teva expands its central nervous system (CNS) portfolio with ZECUITY, the first prescription migraine patch approved by the FDA for the acute treatment of migraine in adults....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters